Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
I more or less a just quoted from the article, didn't really look into the details on my own:

And the bempegaldesleukin/Opdivo combo looks less toxic than Opdivo/Yervoy, with around 10% of patients in Pivot-02 discontinuing owing to a treatment-related adverse event at 12 months; the discontinuation rate with Opdivo plus Yervoy is around 40%.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.